cryptocurrency worth less than a penny- Top Featured snippets

Japan's producer price in November increased by 0.3% month-on-month, and it is estimated to increase by 0.2%. Japan's producer price in November increased by 3.7% year-on-year, and it is estimated to increase by 3.4%.Galaxy Securities: Macro-policies have increased the accumulation of positive factors in bank fundamentals. The china galaxy Securities Research Report said that the macro-policy upgrade has exceeded expectations and supported the growth of bank credit. Bank spreads are still under pressure, but the release of debt cost optimization results is expected to form support. Preventing and resolving the risk orientation in key areas remains unchanged, and the asset quality and risk expectation of banks are expected to benefit. The positive factors in the fundamentals of banking operations have accumulated, and we will continue to be optimistic about the allocation value of the banking sector and maintain the recommended rating. For individual stocks, ICBC, China Construction Bank, Postal Savings Bank, Jiangsu Bank and Changshu Bank are recommended.Navigation warning! Sea shooting test in the southern Yellow Sea, according to the website of China Maritime Safety Administration, Lianyungang Maritime Safety Administration issued a navigation warning. From 8: 00 to 14: 00 on December 11, some sea areas in the southern Yellow Sea were fired with live ammunition, and it was forbidden to enter.

Guotai Junan's annual strategy for innovative drugs in 2025: innovative pharmaceutical companies have accelerated into the harvest period, and the valuation has been at a historical low in the past five years. Guotai Junan said that the centralized purchasing policy has become stable, mature and normalized, and the marginal impact has weakened. Innovative drugs have gained policy inclination in the medical insurance negotiation. In the past two years, the policy has continued to promote pharmaceutical innovation, and the top-level design and local supporting chain support the development of innovative drugs. Commercial insurance is expected to bring new growth momentum to China's pharmaceutical market, and the overall industry trend is upward. At present, the trend of innovative drug industry is improving, the supply continues to accelerate, and a number of domestic innovative drugs are approved soon, which is expected to drive a new round of heavy volume. At the same time, the commercialization has achieved remarkable results and has occupied a dominant position in some sub-sectors. Pharma's performance continued to differentiate, and innovative drugs and just-needed drugs performed well. Biotech commercialization continues to increase, per capita yield continues to increase, the node of turning losses is approaching, and innovation ushers in the harvest period. Horizontal comparison: compared with overseas peers, the overall valuation of domestic innovative pharmaceutical companies is in a historically low range; Vertical comparison: the valuation of SW- pharmaceutical biology and SW- chemical preparations is at a historical low in the past five years, and it is expected that the valuation of subsequent sectors will pick up.Policy combination boosts confidence, and public offering: China's assets will usher in a further increase in valuation. On December 9, the Political Bureau of the Communist Party of China (CPC) Central Committee held a meeting to analyze and study the economic work in 2025. A number of public offerings said that the meeting sent a very positive signal. At present, the economy is resilient, the investor structure is constantly optimized, and the market activity continues to increase. China assets may have an opportunity to raise their valuations again. From the perspective of funds, Jing Shun Great Wall Fund analyzed that the current A-share market is in the most active stage since 2015, and there are many potential bulls in the market. Policy expectations are expected to drive incremental funds into the market, forming a resonance between emotions and funds. (SSE)ADB lowered the growth forecast of developing economies in the Asia-Pacific region to maintain China's economic growth forecast. On December 11th, the Asian Development Bank issued the Asia Development Outlook 2024 (December Edition). According to the report, the development momentum in the Asia-Pacific region is steady, but as US President-elect Trump is about to take office, changes in his trade, finance and immigration policies may inhibit the development of the Asia-Pacific region and aggravate inflation. ADB lowered its growth forecast for developing economies in the Asia-Pacific region from the previous 5.0% to 4.9% in 2024, and from the previous 4.9% to 4.8% in 2025. China's economic growth is expected to remain at 4.8% and 4.5% in 2024 and 2025 respectively, which is the same as before.

Luckin Coffee will open seven stores in Mong Kok, Tsim Sha Tsui and Sheung Wan. (Sing Tao Daily)Caoji Group seeks to raise up to HK$ 138 million through Hong Kong IPO. According to the announcement of the Hong Kong Stock Exchange, Caoji Group will issue about 33.3 million shares at a price range of HK$ 3.75 to HK$ 4.15 per share. The company may raise up to HK$ 138 million (US$ 17.8 million) and is expected to start listing on December 19th.SpaceX is valued at about $350 billion due to internal stock sales. According to an email sent to employees seen by the media, SpaceX and its investors have agreed to acquire the company's common stock of up to $1.25 billion at a price of $185 per share. This transaction values elon musk's rocket and satellite manufacturer at about $350 billion.